Recent advances in the management of autoimmune pancreatitis in the era of artificial intelligence

Table 2 Summary table of the International Consensus Diagnostic Criteria for autoimmune pancreatitis-1[10]

ICDC	Level 1	Level 2
P: Parenchymal imaging	Typical: Diffuse enlargement with delayed enhancement (rim-like enhancement)	Indeterminate: Segmental or focal enlargement with delayed enhancement
D: Ductal imaging	Single long stricture (> 1/3 length of MPD) or multiple stricture without marked upstream dilatation	Segmental or focal narrowing without marked upstream dilatation (< 5 mm)
S: Serology	IgG4 > 2x upper limit of normal value (> 2.70 g/L)	IgG4 rate: 1-2x upper limit of normal value
OOI: Other organ involvement	Histology of extra-pancreatic organ (3/4)	Histology of extra-pancreatic organ must show both: (1) Periductal lympho-plasmacytic infiltration without granulocyte epithelial lesions; and (2) > 10 cells/HPF of IgG4 positive cells
	Typical radiological evidence: (1) Stenosis of intrahepatic bile duct or proximal and distal common bile duct; and (2) Retroperitoneal fibrosis	Physical or radiological evidence (1/2): (1) Symmetrically enlarged salivary/lachrymal glands; and (2) Radiological renal involvement
H: Pancreatic histology	3/4 criteria	2/4 criteria
Periductal lymphoplasmacytic infiltration without granulocyte epithelial lesions
Obliterative phlebitis
Storiform fibrosis
> 10 cells/HPF of IgG4 positive cells
Rt: Corticosteroid response	Rapid (≤ 2 wk) radiologically demonstrable resolution or marked improvement in pancreatic/extrapancreatic manifestation

HPF: High power field; ICDC: International Consensus Diagnostic Criteria; IgG: Immunoglobulin G; MPD: Main pancreatic duct.